Bessemer Group Inc. Sells 174 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Bessemer Group Inc. trimmed its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 3.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 5,078 shares of the biopharmaceutical company’s stock after selling 174 shares during the period. Bessemer Group Inc.’s holdings in Regeneron Pharmaceuticals were worth $3,617,000 at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. Virtu Financial LLC bought a new position in shares of Regeneron Pharmaceuticals in the 3rd quarter worth $6,364,000. Morse Asset Management Inc lifted its stake in Regeneron Pharmaceuticals by 0.9% in the third quarter. Morse Asset Management Inc now owns 4,807 shares of the biopharmaceutical company’s stock valued at $5,053,000 after buying an additional 43 shares during the period. Anchor Investment Management LLC boosted its holdings in Regeneron Pharmaceuticals by 212.0% during the third quarter. Anchor Investment Management LLC now owns 858 shares of the biopharmaceutical company’s stock worth $902,000 after buying an additional 583 shares during the last quarter. Sculati Wealth Management LLC grew its position in shares of Regeneron Pharmaceuticals by 1.9% during the 3rd quarter. Sculati Wealth Management LLC now owns 2,047 shares of the biopharmaceutical company’s stock worth $1,970,000 after buying an additional 38 shares during the period. Finally, Pine Valley Investments Ltd Liability Co increased its stake in shares of Regeneron Pharmaceuticals by 19.0% in the 3rd quarter. Pine Valley Investments Ltd Liability Co now owns 5,303 shares of the biopharmaceutical company’s stock valued at $5,575,000 after acquiring an additional 848 shares during the last quarter. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

REGN has been the topic of several recent analyst reports. Citigroup reduced their price objective on shares of Regeneron Pharmaceuticals from $795.00 to $750.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 28th. Canaccord Genuity Group cut shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, December 17th. Piper Sandler lowered their price objective on shares of Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an “overweight” rating for the company in a research report on Monday, January 27th. Sanford C. Bernstein reduced their target price on Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating on the stock in a report on Tuesday, January 7th. Finally, Truist Financial decreased their target price on Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a “buy” rating for the company in a research note on Wednesday, January 8th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have assigned a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $966.88.

Regeneron Pharmaceuticals Trading Up 1.4 %

NASDAQ REGN opened at $554.18 on Friday. Regeneron Pharmaceuticals, Inc. has a 12 month low of $525.99 and a 12 month high of $1,211.20. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09. The stock has a 50 day moving average of $659.94 and a 200-day moving average of $755.22. The company has a market cap of $60.59 billion, a PE ratio of 14.48, a PEG ratio of 2.34 and a beta of 0.44.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, beating analysts’ consensus estimates of $11.21 by $0.86. The firm had revenue of $3.79 billion during the quarter, compared to analysts’ expectations of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The company’s revenue for the quarter was up 10.3% compared to the same quarter last year. During the same quarter last year, the company posted $11.86 earnings per share. On average, equities research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, March 20th. Investors of record on Thursday, February 20th were issued a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a yield of 0.64%. The ex-dividend date was Thursday, February 20th. Regeneron Pharmaceuticals’s payout ratio is currently 2.30%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.